Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study

被引:160
|
作者
Elias, D
Lasser, P
Ducreux, M
Duvillard, P
Ouellet, JF
Dromain, C
Schlumberger, M
Pocard, M
Boige, V
Miquel, C
Baudin, E
机构
[1] Inst Gustave Roussy, Dept Surg Oncol, Ctr Comprehens Canc, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Med Oncol, Ctr Comprehens Canc, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Pathol, Ctr Comprehens Canc, F-94805 Villejuif, France
[4] Inst Gustave Roussy, Dept Radiol, Ctr Comprehens Canc, F-94805 Villejuif, France
[5] Inst Gustave Roussy, Dept Nucl Med, Ctr Comprehens Canc, F-94805 Villejuif, France
[6] Inst Gustave Roussy, Endocrine Tumor Unit, Ctr Comprehens Canc, F-94805 Villejuif, France
关键词
D O I
10.1067/msy.2003.114
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. The timing and benefits of hepatectomy remain controversial for metastatic well-differentiated endocrine neoplasms, which are generally considered slow growth tumors. However, surveillance alone yields only a 22% 5-year survival when metastases occur. The aim of this study was to determine the results of hepatic and extra hepatic resections and to clarify the indications of surgery. Methods. To define the role of hepatic resection, a database regrouping all patients (n = 47) who underwent hepatectomy with curative intent (R0 status) for well-differentiated endocrine neoplasms in the Gustave-Roussy Institute was constructed in 1984. New Prognostic factors such as tumor growth and liver tumor mitotic index were studied. Median follow-up was 62 months. Results. Hepatectomy was associated with extrahepatic tumor resection in 77% of the patients (Primary tumor in 51%, lymph nodes in 21%, peritoneal carcinomatosis in 25%, and other in 6%). Resection was curative (R0) only in 53% of the patients, despite removing at least 97% of the tumor in each patient. Mortality was 5%, and morbidity was 45%. Median survival was 91 months, 5-year and 10-year overall survival rates were 71% and 35%, respectively.. Liver recurrence rate was 75% at 10 years. No Prognostic factor was correlated with overall survival in this population in which at least 97% of the tumor load was resected. The completeness of surgery, the presence of bilateral liver metastases, the number of liver metastases (>10) and a Primary tumor from Pancreatic origin were all significantly correlated with the disease free survival. Preoperative tumor growth rate, mitotic index, and Ki67 expression were not predictive of prognosis. No significant Prognostic factors could be found by the comparison of the patients who did and did not recur during the 3 years after hepatectomy. Conclusion. Hepatectomy for liver metastases from well-differentiated endocrine neoplasms is indicated when all visible intra- and extra hepatic lesions can be resected safely. The number, size, and localization of the tumor sites are less important than performing a complete (or near-complete) resection.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 32 条
  • [1] A 15-Year Review of Well Differentiated Gastric and Duodenal Neuroendocrine Tumors (NETs): A Single Center Retrospective Study
    Patwardhan, Soumil S.
    Meunier, Rashna
    Basil, Anjali
    Wang, Xiaofei
    Cave, David R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S482 - S483
  • [2] Surgical resection of metastatic pancreatic cancer: is it worth it? -a 15-year experience at a single Chinese center
    Gu, Jiangning
    Xu, Zhiwei
    Ma, Yang
    Chen, Hao
    Wang, Di
    Deng, Xiaxing
    Cheng, Dongfeng
    Xie, Junjie
    Jin, Jiabin
    Zhan, Xi
    Shi, Yuan
    Shi, Yusheng
    Zhu, Youwei
    Shen, Baiyong
    Peng, Chenghong
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (02) : 319 - +
  • [3] A PHASE II TRIAL OF BEVACIZUMAB WITH CAPECITABINE IN PROGRESSIVE, METASTATIC WELL-DIFFERENTIATED DIGESTIVE ENDOCRINE TUMORS (BETTER STUDY)
    Walter, T. A.
    Baudin, E.
    Kurtz, J. E.
    Ruszniewski, P.
    Bengrine-Lefevre, L.
    Cadiot, G.
    Dominguez-Tinajero, S.
    Kraemer, S.
    Ducreux, M. P.
    Mitry, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 378 - 378
  • [4] Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study
    Maire, Frederique
    Lombard-Bohas, Catherine
    O'Toole, Dermot
    Vullierme, Marie-Pierre
    Rebours, Vinciane
    Couvelard, Anne
    Pelletier, Anne Laure
    Zappa, Magaly
    Pilleul, Frank
    Hentic, Olivia
    Hammel, Pascal
    Ruszniewski, Philippe
    [J]. NEUROENDOCRINOLOGY, 2012, 96 (04) : 294 - 300
  • [5] Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).
    Mitry, Emmanuel
    Walter, Thomas
    Baudin, Eric
    Kurtz, Jean-Emmanuel
    Ruszniewski, Philippe
    Dominguez, Sophie
    Bengrine-Lefevre, Leila
    Cadiot, Guilaume
    Kraemer, Sandrine
    Ducreux, Michel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Risk Factors and Outcomes of Postoperative Recurrent Well-Differentiated Thyroid Cancer: A Single Institution's 15-Year Experience
    Amin, Shaunak N.
    Shinn, Justin R.
    Naguib, Mark M.
    Netterville, James L.
    Rohde, Sarah L.
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2020, 162 (04) : 469 - 475
  • [7] Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience
    Aliseda, Daniel
    Marti-Cruchaga, Pablo
    Zozaya, Gabriel
    Rodriguez-Fraile, Macarena
    Bilbao, Jose I.
    Benito-Boillos, Alberto
    de la Cuesta, Antonio Martinez
    Lopez-Olaondo, Luis
    Hidalgo, Francisco
    Ponz-Sarvise, Mariano
    Chopitea, Ana
    Rodriguez, Javier
    Inarrairaegui, Mercedes
    Herrero, Jose Ignacio
    Pardo, Fernando
    Sangro, Bruno
    Rotellar, Fernando
    [J]. CANCERS, 2023, 15 (03)
  • [8] Liver transplantation for patients with metastatic endocrine tumors: Single-center experience with 15 patients
    Frilling, A
    Malago, M
    Weber, F
    Paul, A
    Nadalin, S
    Sotiropoulos, GC
    Cicinnati, V
    Beckebaum, S
    Bockisch, A
    Mueller-Brand, J
    Hofmann, M
    Schmid, KW
    Gerken, G
    Broelsch, CE
    [J]. LIVER TRANSPLANTATION, 2006, 12 (07) : 1089 - 1096
  • [9] Report of 177Lu-DOTATATE Therapy in Patients with Well-differentiated Metastatic Neuroendocrine Tumors: A Single Center Experience
    Abiodun-Ojo, Olayinka
    Shaib, Walid
    Fourzali, Yamil
    Rupji, Manali
    Switchenko, Jeffrey
    Muzahir, Saima
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [10] Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors
    Fine, Robert Lance
    Gulati, Anthony Paul
    Tsushima, Dawn
    Mowatt, Kelley B.
    Oprescu, Anna
    Bruce, Jeffrey N.
    Chabot, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)